Physician profile
Amit Arora
NPI 1831378330
$3,124.00
in general payments reported to CMS, 2019-2025
30 companies · $756 in 2025
The $756 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $53.58 · 2021: $87.42 · 2022: $398 · 2023: $766 · 2024: $514 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014 · Education: $21.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,014.12 |
| Education | $21.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $424.56 | 2019-2024 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $293.76 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $255.02 | 2023-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $220.54 | 2021-2025 | |
| Novo Nordisk INC | $185.18 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.35 | 2023-2025 | Jardiance |
| Edwards Lifesciences Corporation | $164.52 | 2023 | |
| Mallinckrodt Hospital Products INC. | $162.36 | 2023-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $147.63 | 2019-2025 | Thiola |
| Fresenius USA Marketing, INC. | $127.19 | 2019-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $98.69 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $90.63 | 2019 | |
| Merck Sharp & Dohme LLC | $85.85 | 2019 | |
| Vifor Pharma, INC. | $85.70 | 2019-2022 | |
| Horizon Therapeutics Plc | $83.25 | 2021-2023 | Krystexxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $82.17 | 2019 | |
| Daiichi Sankyo INC. | $72.55 | 2021-2023 | Injectafer |
| Calliditas Therapeutics US INC. | $66.64 | 2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $65.82 | 2019 | |
| Aurinia Pharma U.S., INC. | $45.15 | 2024 | Lupkynis |
| Akebia Therapeutics INC | $26.22 | 2025 | Vafseo |
| Ani Pharmaceuticals, INC. | $24.99 | 2023 | Purified Cortrophin Gel |
| Ardelyx, INC. | $24.16 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $23.79 | 2025 | Ultomiris |
| Lilly USA, LLC | $20.36 | 2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $20.26 | 2023 | Keveyis |
| Scpharmaceuticals INC. | $20.12 | 2025 | |
| Opko Pharmaceuticals, LLC | $16.10 | 2023 | Rayaldee |
| Shire North American Group INC | $14.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.